ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0338

Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors

Jeffrey X. Yang1, Mehmet Hocaoglu2, Jose A Meade-Aguilar1, Alain Sanchez-Rodriguez1, Mark Denis P Davis3, Hannah Langenfeld4, Cynthia Crowson5 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2University of Maryland Medical Center, Midtown Campus, Baltimore, MD, 3Mayo Clinic, Rochester, 4Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 5Mayo Clinic, Eyota, MN

Meeting: ACR Convergence 2022

Keywords: Cohort Study, Dermatology, longitudinal studies, risk factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Smoking and use of estrogen-containing oral contraceptives (OCP) are SLE risk factors. Data on transitioning from cutaneous lupus erythematosus (CLE) to SLE and potential risk factors associated with that transition remains limited. We aimed to determine the transition rate from CLE to SLE and its associated factors.

Methods: Incident CLE cases were identified based on the modified Gilliam classification scheme in a 27-county region of the American Upper Midwest from 1976-2018. Incident SLE cases were defined according to the European Alliance of Associations for Rheumatology/American College of Rheumatology (EULAR/ACR) criteria. Patients with prior or concurrent SLE diagnosis (SLE diagnosis within 90 days of CLE diagnosis) were excluded. Demographics, BMI, smoking, estrogen-containing OCP use, and CLE subtype were abstracted. CLE patients were followed until SLE diagnosis, death, or emigration out of the 27-county region. Aalen-Johansen methods were used to calculate transition rates from CLE to SLE. Cox-proportional hazards models were used to estimate factors associated with the transition.

Results: 356 incident CLE cases were identified. 15 were excluded due to the presence of SLE before CLE, and 17 more were excluded due to concurrence of CLE and SLE within 90 days. 324 cases were included in the analysis. During a median follow-up of 8.15 years, 26 patients transitioned to SLE. 20 years after CLE diagnosis 11.8% of CLE patients transitioned to SLE. 5.2% transitioning by 5 years and < 3% transitioning every 5 years from 5-20 years (Figure 1).

Patients with CLE 40 years or younger were more likely to transition to SLE (hazard ratio [HR] 3.25, 95% confidence interval [CI] 1.31 – 8.05) than those older than 50 years. Patients with subacute cutaneous lupus erythematosus (SCLE) were more likely to transition to SLE compared to patients with discoid lupus erythematosus (DLE) (HR 3.6, 95% CI 1.6 – 8.1) and patients with other types of chronic CLE (lupus panniculitis, chilblain lupus or lupus tumidus) (HR 9.3, 95% CI 1.2 – 72.2). Race, sex, family history, calendar year, obesity, smoking, use of estrogen-containing OCPs, and past medical history were not associated with CLE to SLE transition.

Conclusion: The CLE to SLE transition occurred more frequently in patients aged 40 and younger, within the first 10 years of diagnosis, and those with SCLE. Other risk factors studied, including race, sex, family history, calendar year, obesity, smoking, estrogen-containing OCPs, and PMHs, did not affect transitioning.

Supporting image 1

Figure 1. Cumulative incidence of systemic lupus erythematosus among patients with cutaneous lupus erythematosus in a 27-county region, 1976_2018.


Disclosures: J. Yang, None; M. Hocaoglu, None; J. Meade-Aguilar, None; A. Sanchez-Rodriguez, None; M. Davis, None; H. Langenfeld, None; C. Crowson, None; A. Duarte-Garcia, None.

To cite this abstract in AMA style:

Yang J, Hocaoglu M, Meade-Aguilar J, Sanchez-Rodriguez A, Davis M, Langenfeld H, Crowson C, Duarte-Garcia A. Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/transitioning-from-cutaneous-to-systemic-lupus-erythematosus-an-analysis-of-incidence-and-risk-factors/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/transitioning-from-cutaneous-to-systemic-lupus-erythematosus-an-analysis-of-incidence-and-risk-factors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology